<DOC>
	<DOCNO>NCT02999763</DOCNO>
	<brief_summary>Prospective , one-arm , baseline-controlled , clinical study evaluation SlimShape device non-invasive abdominal fat circumference reduction . Study subject undergo SlimShape treatment abdominal area .</brief_summary>
	<brief_title>SlimShape Device Abdominal Fat Circumference Reduction</brief_title>
	<detailed_description>The objective trial evaluate safety efficacy SlimShape device utilize SlimShape Applicator Belt abdominal non-invasive fat circumference reduction . Eligible subject receive 3 bi-weekly treatment ( 2 week interval ) SlimShape device utilize SlimShape Applicator Belt accord study protocol . The subject return 3 follow visit : four week ( 4wk FU ) , eight week ( 8wk FU ) 12 week ( 12wk FU ) last treatment . Each subject enrol total expect study duration 16 week .</detailed_description>
	<mesh_term>Lipid Metabolism Disorders</mesh_term>
	<criteria>1 . Signed informed consent participate study . 2 . Female male subject , ≥18 ≤60 year age time enrollment 3 . Fitzpatrick Skin Type I VI 4 . BMI interval : 18.5 ≤ BMI ≤ 30 ( normal overweight , obese ) . 5 . If female , pregnant , lactate must either postmenopausal , surgically sterilize , use medically acceptable form birth control least 3 month prior enrollment ( i.e. , oral contraceptive , contraceptive implant , barrier method spermicide abstinence ) . 6 . In addition , negative urine pregnancy test test treatment last visit woman childbearing potential ( e.g . menopause ) . 7 . General good health confirm medical history skin examination treat area . 8 . Willing follow treatment followup schedule posttreatment care instruction . 9 . Willing refrain change diet/ exercise/medication regimen entire course study . 10 . Willing photograph image take treated area use deidentified evaluation , publication presentation . 1 . History hypertension , ischemic heart disease , valvular heart disease , congestive heart failure , pacemaker/defibrillator , abdominal aortic aneurism 2 . Current hyperlipidemia , diabetes mellitus , hepatitis , liver disease , HIV positive status , blood coagulopathy excessive bleeding , autoimmune connective tissue disease 3 . Having undergoing form treatment active cancer , history skin cancer cancer area treat , include presence malignant pre‐malignant pigment lesion 4 . Having active electrical implant anywhere body , pacemaker internal defibrillator 5 . Having permanent implant treat area , metal plate inject chemical substance silicone 6 . Having undergone surgery treat area within 12 month treatment study , include liposuction 7 . Previous body contour procedure treatment area within 12 month 8 . History skin disease treatment area , know tendency form keloid poor wound heal 9 . History epidermal dermal disorder ( particularly involve collagen microvascularity ) 10 . Suffering significant skin condition treat area inflammatory skin condition , include , limited , open laceration abrasion active cold sore herpes sore prior treatment ( duration resolution per Investigator 's discretion ) treatment course 11 . Allergy component lotion ( VelaSpray Ease ) use study 12 . Skin lesion treatment area simple nevi physical examination ( e.g. , atypical nevus , tattoo , abrasion ) include depressed scar treatment area 13 . Very poor skin quality ( i.e. , severe laxity ) 14 . Abdominal wall diastasis hernia physical examination 15 . Abnormal kidney , liver coagulation function , abnormal lipid profile blood count within last 3 month 16 . Obesity ( BMI &gt; 30 ) 17 . Childbirth within last 12 month breastfeed woman . Any acute chronic condition , opinion investigator , could interfere conduct study 18 . Unstable weight within last 6 month ( i.e. , ± 3 % weight change prior six month ) 19 . Inability comply circumference measurement procedure ( e.g. , inability hold breath require duration ) . 20 . Participation another clinical study involve anatomical area within last 6 month ( 30 day case different anatomical area treat previous trial/s ) . 21 . As per Investigator 's discretion , physical mental condition might make unsafe subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>lipolysis</keyword>
	<keyword>fat reduction</keyword>
	<keyword>circumference reduction</keyword>
</DOC>